Sildenafil and the Heart: Cardiac Contraindications and Precautions
Primary Recommendation
Sildenafil is safe for use in men with stable cardiovascular disease who can achieve ≥5 METs of exercise capacity without symptoms, but is absolutely contraindicated with concurrent nitrate use. 1
Absolute Contraindications
The only absolute contraindication for sildenafil is concurrent use of organic nitrates in any form (regular or intermittent), as this combination causes severe, potentially life-threatening hypotension 1, 2, 3. No nitrates should be used within 24 hours of sildenafil administration 3, 4.
Additional absolute contraindications include:
Cardiovascular Safety Profile
Sildenafil produces modest hemodynamic effects that are generally well-tolerated:
- Mean blood pressure reduction: 8.3/5.3 mmHg in healthy volunteers 1
- No clinically significant ECG changes at doses up to 100 mg 1
- Does not affect cardiac contractility or increase ventricular arrhythmia risk 2
- In patients with stable ischemic heart disease, sildenafil was statistically non-inferior to placebo for time to limiting angina during exercise testing 1
Risk Stratification for Sexual Activity
Before prescribing sildenafil, assess whether the patient can safely engage in sexual activity, which typically requires 3-5 METs of energy expenditure 5, 3, 6. The key threshold is:
Patients who can exercise at ≥5 METs without angina, excessive dyspnea, ischemic ST-segment changes, cyanosis, hypotension, or arrhythmia can safely resume sexual activity 5.
Practical assessment:
- Sexual activity averages 2.5-3.3 METs during stimulation/orgasm 3
- Equivalent to walking 3-4 mph or climbing 2 flights of stairs briskly 5
- 6-minute walk test can assess stability in heart failure patients 5
Specific Cardiac Populations
Stable Coronary Artery Disease
Sildenafil is safe in men with stable angina controlled on medications (excluding nitrates) 7, 2, 6. Clinical trials showed no increased incidence of myocardial infarction, cardiovascular death, or total mortality compared to placebo 6.
Heart Failure
Use caution in patients with heart failure 3, 8. Patients unable to complete a 6-minute walk test or achieve 3-5 METs may not tolerate the exertion of sexual activity 5.
Uncontrolled Hypertension or Hypotension
Safety has not been established in patients with uncontrolled hypertension or hypotension 2. Consult current prescribing information before use.
Recent Cardiovascular Events
Safety has not been established in patients with recent serious cardiovascular events 2. Exercise caution and consider deferring treatment until cardiovascular stability is achieved.
Drug Interactions Requiring Caution
Alpha-Blockers
Use sildenafil with caution in patients on alpha-blockers due to risk of symptomatic hypotension 1, 2. Management approach:
- Ensure patient is stable on alpha-blocker therapy first
- Initiate sildenafil at the lowest dose (25 mg)
- Similar caution applies to mixed alpha/beta blockers (carvedilol, labetalol) 2
Calcium Channel Blockers
In controlled studies with amlodipine, mean additional blood pressure reduction was 8/7 mmHg 2. Monitor for excessive hypotension.
Antihypertensive Medications
The adverse event profile is similar between patients taking and not taking antihypertensive drugs 2. However, caution is necessary with combination antihypertensive regimens 3.
Dose Adjustments for Cardiac Patients
Start with 25 mg in patients with:
- Age >65 years 1
- Severe renal impairment (CrCl <30 mL/min) - results in approximately doubled AUC and Cmax 1
- Hepatic impairment (Child-Pugh A or B) - results in 85% increased AUC 1
- Concurrent use of potent CYP3A4 inhibitors (erythromycin, cimetidine, certain statins) 3
Warning Signs During Sexual Activity
Patients should report these symptoms immediately 5:
- Chest pain unrelieved by nitroglycerin (if prescribed for non-sexual activity contexts)
- Shortness of breath
- Rapid or irregular heart rate
- Dizziness
- Insomnia after sexual activity
- Fatigue the day after sexual activity
Critical caveat: If chest pain occurs during or after sexual activity in a sildenafil user, do NOT administer nitrates. Treat according to acute coronary syndrome guidelines with aggressive fluid resuscitation, vasoactive drugs if needed, and potentially intraaortic balloon counterpulsation for severe hypotension 3.
Cardiovascular Risk Assessment
ED itself is an early warning sign of cardiovascular disease due to shared risk factors and endothelial dysfunction 9. Any man presenting with ED without obvious cause (e.g., trauma) should undergo:
- Screening for vascular disease
- Blood glucose, lipid panel, and blood pressure measurements 9
- Ideally, elective exercise ECG for risk stratification in asymptomatic patients 9
The concept: A man with ED and no cardiac symptoms is a cardiac patient until proven otherwise 9.
Chronic Cardiac Pathology Considerations
Recent postmortem data suggests sildenafil users have greater burden of chronic cardiac pathology, particularly coronary calcification, though no excess acute ischemic pathology 10. This underscores the importance of comprehensive cardiovascular risk assessment before prescribing.
Practical Clinical Algorithm
- Screen for absolute contraindications: nitrate use, severe aortic stenosis, HOCM
- Assess exercise capacity: Can patient achieve ≥5 METs without cardiac symptoms?
- Evaluate drug interactions: alpha-blockers, multiple antihypertensives, CYP3A4 inhibitors
- Determine appropriate starting dose: 25 mg for age >65, renal/hepatic impairment, or drug interactions; otherwise 50 mg
- Counsel on warning signs and emergency management (no nitrates within 24 hours)
- Encourage regular exercise to reduce risk of sexual activity-triggered MI 5